IRP Research Leads to First FDA-Approved Therapy for Merkel Cell Carcinoma
By Melissa Glim
Tuesday, May 4, 2021
May is Skin Cancer Awareness Month. Skin cancers are the most common cancer in the U.S., affecting as many as five million people every year. Yet the rarest of these cancers is also one of the deadliest. Merkel cell carcinoma affects about 3,000 Americans each year, and until recently a lack of effective treatments meant only half of patients survived five years or longer after diagnosis. The median survival was nine months.
This bleak outlook changed radically in 2017 with the US Food and Drug Administration (FDA) approval of a new immunotherapy drug called avelumab. Developed through a collaboration between IRP researchers and the pharmaceutical company EMD Serono, Inc., and marketed as Bavencio, avelumab was the first treatment approved specifically for Merkel cell carcinoma.
Modifying Tumor’s Surroundings Stymies Cancer’s Expansion
By Brandon Levy
Tuesday, December 10, 2019
If you ever tried planting an apple tree in the desert or growing avocados in New England, you would quickly figure out that such plants need a particular environment in order to thrive. Cancerous tumors are no different, and IRP researchers recently found strong evidence that a molecule naturally produced in the body can suppress the growth and spread of a particularly lethal form of breast cancer via both direct effects on the cancer and by altering its surroundings.
By Alex Szatmary
Thursday, July 14, 2016
As a theoretician in the lab of Dr. Ralph Nossal (NICHD), I use mathematical modeling to study how cells get to places in the body. Most of my time is focused on completing clearly written goals born from project plans. A system of timers, project plans, and goals keeps me on track to do what I need to do so that I can get back to the fun part of my job that I would happily do for free.
